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Abstract 
Aim: This study examined the use and adverse reactions of second-generation antipsychotics 
(SGAs), alone or combined with other psychotropic medication, to identify areas for 
standardising prescribing and monitoring practices.  
Methods: We conducted a retrospective study at Tampere University Hospital, Finland, 
involving 128 patients (81% boys) who were under 13 years old at SGA initiation and had SGA 
treatment between October 2013 and October 2014. 
Results: The median age at baseline was 9.4 years.  Weight gain was reported as an adverse 
reaction in 33%, but an increase in standardised body mass index, adjusted for age and sex 
(BMI z-score), was detected in 75% of patients with sufficient data. The statistically significant 
median changes during the study were an increase of 0.46 in BMI z-score, a reduction of 0.25 
mmol/l in fasting plasma high-density lipoprotein and an increase of 0.28 mmol/l in triglyceride 
values. The weight gain was most apparent in patients treated with just an SGA or SGA plus 
melatonin. Patients treated with an SGA plus medication for attention deficit hyperactivity 
disorder were less likely to gain weight.  
Conclusion: SGA-induced metabolic disturbances remained partly unrecognised in children 
under 13 years of age and more systematic monitoring is needed. 
  
Key Notes 
• We examined the use and adverse reactions of second-generation antipsychotics 
(SGAs), alone or combined with other psychotropic medication, in 128 children (81% 
boys) under the age of 13.  
• Our findings showed that statistically significant weight gain and deteriorating fasting 
plasma triglycerides and high-density lipoproteins were associated with SGA 
treatment. 
• Implementing systematic prescribing and monitoring practices for SGA treatment in 
paediatric patients is essential, as many negative changes currently go unrecognised. 
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INTRODUCTION 
The use of psychotropic medication and polypharmacy has increased among paediatric 
patients (1-4). The use of second-generation antipsychotics (SGAs) has particularly emerged, 
as has the use of stimulants, other medication for attention deficit and hyperactivity disorder 
(ADHD) and melatonin (4,5). Paediatric patients have been reported to be especially 
vulnerable to SGA-induced metabolic adverse reactions, such as weight gain, glucose and 
lipid abnormalities and elevated blood pressure (2,3,6-8). The risk of type 2 diabetes has been 
reported to be two to three times higher in children treated with SGAs (9). Adverse metabolic 
reactions have been associated with a markedly increased risk of cardiovascular disease, 
especially with long-term SGA treatment (2). A study published in 2019 also showed an 
association between antipsychotic treatment and unexpected deaths in children and 
adolescents (10). In the short term, SGAs have been shown to induce similar neurological 
adverse reactions in children and adults (11). Longer treatment may be associated with more 
severe manifestations, such as tardive dyskinesia (3,12). SGAs are sometimes used to 
augment methylphenidate and atomoxetine – henceforth referred to as ADHD medication – to 
treat comorbid aggression in ADHD (13). ADHD medication has been reported to reduce 
weight, while SGA appears to have the opposite effect (14,15). However, subjects with ADHD 
did gain weight when risperidone was combined with methylphenidate (13). 
 
These findings highlight the need for proper monitoring practices for children treated with 
SGAs. There are guidelines on follow-up practices, but there has been limited systematic 
monitoring, despite the evidence of SGA-related adverse reactions (16-20). 
 
The aim of this study was to find potential areas of clinical practice where prescribing and 
monitoring of SGA medication administered to children could be standardised. We did this by 
examining the use and adverse reactions of SGAs, alone or when combined with other 
psychotropic medication.  
 PATIENTS AND METHODS 
This retrospective study of medical records was conducted at the child psychiatric clinic of 
Tampere University Hospital and it was approved by the ethics committee of Pirkanmaa 
Hospital District. We included patients who were prescribed SGA at our child psychiatric clinic 
when they were less than 13 years of age and received SGA treatment between 1 October 
2013 to 1 October 2014. They were only included if any treatment breaks did not exceed six 
months. These criteria were met by 128 patients. We examined medical reports from SGA 
initiation. The study end point for each patient was whichever came first: when they 
discontinued SGA, when they discontinued treatment at the child psychiatric clinic or 31 May 
2015. Sociodemographic factors, diagnoses and the psychiatric and any other medical history 
of the patient and their family were recorded. Information on SGA and other psychotropic 
medication use, follow-up practices, reported adverse reactions and paediatric consultations 
were also collected from the medical records. 
 
If the patient’s weight and height, collected from the medical records, were both measured at 
the same time point, the standardised body mass index adjusted for age and sex (BMI z-score) 
was calculated using Finnish national growth reference tables (21). Based on the 
recommendations of the International Obesity Task Force expert panel, the BMI percentile 
curves passing through BMIs of 25 kg/m2 and 30 kg/m2 at the age of 18 years were used to 
define the limits for overweight and obesity, respectively (21). These were the 87.8th and 98.2th 
percentile for the girls and the 78.2th and 95.6th percentile for the boys. The minimum and 
maximum BMI z-scores were identified when at least two BMI z-scores were available. These 
were either one at baseline and at least one follow-up value or at least two follow-up values. 
The BMI z-scores were rounded to one decimal place to avoid detecting minimal changes. A 
maximum score occurring after a minimum score was considered weight gain during the study 
period and vice-versa for weight loss. 
 Fasting plasma high-density lipoprotein (HDL), triglyceride, and glucose values were collected 
from laboratory reports, and blood pressure values were collected from the children’s medical 
records. Abnormal fasting plasma values were defined as the cut-off points of the National 
Cholesterol Education Program for metabolic syndrome in children and adolescents, namely 
HDL ≤ 1.03 mmol/l, triglycerides ≥ 1.24 mmol/l and glucose > 6.1 mmol/l (22,23). Elevated 
blood pressure was defined using the age, sex, and height-specific reference tables of the 
American Academy of Pediatrics’ Clinical Practice Guideline for Screening and Management 
of High Blood Pressure in Children and Adolescents (24). The percentile of each blood 
pressure measurement was set according to the guideline if a height measurement was 
available within two months of that measurement. Blood pressure was considered elevated if 
it was ≥ 90th percentile on three separate occasions, with at least a week between the readings 
and hypertensive if it was ≥ 95th percentile using the same criteria.  
 
Because of the potential effects of ADHD medication on growth and blood pressure, the study 
population was initially divided into two groups for the analyses: 84 with ADHD medication and 
44 without. To assess the possible effects of melatonin, similar analyses were performed for 
four specific patient groups based on the treatment they had received: just an SGA (n = 23), 
an SGA plus ADHD medication (n = 25), an SGA plus melatonin (n = 21) and an SGA plus 
ADHD medication and melatonin (n = 59).  
 
The categorised variables were reported as numbers of cases or percentages, as appropriate 
and medians and interquartile ranges (IQR, lower to upper quartile) were reported for the 
continuous variables, which were mostly non-normally distributed. To test the statistical 
significance of the differences between the groups, we used Pearson’s chi-square test, 
Fisher’s exact test or the Kruskal–Wallis test, as appropriate. The Kolmogorov–Smirnov test 
was applied to examine whether the changes in BMI z-score, HDL and triglyceride values were 
statistically significant. A p value of less than 0.05 was considered significant, a value between 
0.05 and 0.10 was indicative and values up to 0.10 were reported. SPSS Statistics, versions 
23 and 25 (IBM Corporation, New York, USA) were used for all the statistical analyses.  
 
RESULTS  
The inclusion criteria were met by 128 patients (81% male) with a median age of 9.4 years 
(IQR 7.9 to 11.1) at baseline. The median duration of the SGA treatment was 20.4 months 
(IQR 9.1 to 34.6), but the actual duration was probably longer because of study end-points 
other than SGA discontinuation.  Selected background factors are shown in Table 1 and have 
previously been reported in more detail (25). We found that 120/128 (94%) children were 
treated with risperidone at some point, 23 (18%) with aripiprazole and 22 (17%) with 
quetiapine. The SGA was changed at least once for 28 (22%) children during the follow-up 
period. The use of other psychotropic medication is shown in Table 1.  
 
The follow-up practices are presented in Table 2. The most frequent metabolic test at baseline 
was fasting plasma glucose in 63/128 (49%) patients. The most frequently reported adverse 
reactions by the clinicians were increased appetite in 46 (36%) cases, weight gain in 42 (33%) 
and fatigue in 41 (32%). Neurological adverse reactions, such as akathisia, tics and 
sluggishness or stiffness were reported in 13 patients (10%). During the study period, 39/128 
patients (31%) were referred to a paediatric consultation other than paediatric cardiology. The 
indications for consultations were diverse, but they included 10/39 (26%) who were referred to 
a paediatric endocrinologist due to a metabolic disturbance and 11/39 (29%) who were referred 
to a paediatric neurologist. None of the neurological consultations were due to adverse drug 
reactions. 
 
It was possible to calculate the minimum and maximum BMI z-scores for 97 patients (76%) 
and the cumulative frequency distributions are shown in Figure 1. The BMI z-score increased 
in 73 (75%) of these patients and this increase was within the normal weight category in 40 
(55%) of them (Table 3). The minimum BMI was less than 25 in 74 (76%) patients, whereas 
the maximum BMI was less than 25 in 52 patients (54%). The number of patients who had 
minimum and maximum BMIs that were 25 to < 30 were 16 (17%) and 25 (26%), respectively, 
and for BMIs of 30 or more they were seven (7%) and 20 (21%). The median BMI z-score 
change was an increase of 0.46 (IQR 0.04 to 0.92, p = 0.005). The number of patients for 
whom a BMI z-score could not be calculated at any point was 10/128 (8%). 
 
The frequencies of abnormal metabolic and blood pressure measurements are presented in 
Table 2. At least two fasting plasma HDL and triglyceride values were available for 81/128 
(63%) patients. HDL decreased in 44/81 (54%) and the reduction was within the normal range 
in 39 (89%). The median HDL change was -0.25 mmol/l (IQR -0.43 to -0.15, p = 0.004). 
Triglyceride increases were seen in 44/81 (54%) and these were within the normal range in 36 
(82%). The median triglyceride change was 0.28 mmol/l (IQR 0.11 to 0.46, p < 0.001). 
 
At least three blood pressure percentiles were available for 61/128 (48%) patients: two of them 
(3%) met the criteria for elevated blood pressure and one had hypertension. At least one blood 
pressure percentile was available for 104/128 patients (81%) (Table 2). 
 
The 84 patients treated with SGA plus ADHD medication, with or without melatonin, gained 
weight less frequently than the 44 patients who were just treated with an SGA, with or without 
melatonin (Table 3). Baseline blood pressure was measured for 29/84 patients (35 %) treated 
with SGA plus ADHD medication and 6/44 (14%) (p = 0.013) of those treated with just an SGA. 
At least one blood pressure value during the study period for these groups was available for 
71/84 (85%) and 33/44 (75%), respectively. At least one hypertensive systolic blood pressure 
value was observed in 33/71 (47%) who had ADHD medication combined with an SGA and in 
9/33 (27%) patients who only received SGAs (p = 0.086). We did not find any other statistically 
significant or indicative differences in the baseline or follow-up measurements between these 
two medication groups or in the reported adverse reactions.  
 When we compared all four medication groups, there were no statistically significant 
differences in the baseline or follow-up practices or in the adverse reactions reported by the 
clinicians. Table 3 shows the weight changes in the medication groups. In the 16 patients in 
the SGA plus melatonin group who had at least two BMI z-scores, the weight gain appeared 
within the normal weight category in 11 (69%) patients. The proportion was around one-third 
in the other groups (Table 3). There were no statistically significant differences in triglyceride 
and HDL values between the medication groups. The number of patients with at least one 
hypertensive systolic blood pressure measurement was seven (41%) out of the 17 who were 
treated with just an SGA and had at least one blood pressure measurement during the study 
period. The respective figure was 11/22 (50%) in the group treated with SGA plus ADHD 
medication, 2/16 (13%) in the patients treated with an SGA plus melatonin and 22/49 (45%) in 
the patients treated with an SGA plus ADHD medication and melatonin (p = 0.092). There were 
no statistically significant differences in diastolic blood pressure values between the medication 
groups. 
 
DISCUSSION 
The aim of this study was to find potential areas where prescribing and monitoring practices of 
SGA medication for children could be standardised. Our study findings were in line with 
previous studies that suggested that SGA treatment poses major metabolic risks for children 
(6,7,26). Despite these findings, and the existing guidelines, monitoring practices have often 
remained irregular (16-20). In our study, the baseline information necessary for detecting 
changes in growth and the laboratory test values were seldom complete. In addition, 
information on familial metabolic risk factors was often lacking, which complicates the 
evaluation of possible hereditary risks. 
 
Three-quarters of the patients in our study gained weight and there was also a statistically 
significant deterioration in their triglyceride and HDL values. One of the main findings of this 
study was that these alterations appeared mainly within the normal reference values and 
seemed to remain unrecognised. For example, there was a discrepancy when we compared 
the BMI z-score findings and the frequency of reported weight gain in the medical records. 
Surprisingly, the clinicians only reported weight gain as an adverse reaction in one-third of the 
patients. Nevertheless, even a smaller increase in BMI z-score or alterations in metabolic 
parameters may, without intervention, predict future cardiovascular morbidity. Neurological 
adverse reactions were reported in a tenth of the study patients and this figure was slightly 
lower than in previous studies (11,17). Irregular reporting and the retrospective nature of the 
study may have affected this result. However, the common assumption that SGAs are less 
likely to cause neurological adverse reactions means that there is a risk that these reactions 
are not monitored and may remain unrecognised. Furthermore, misinterpreting neurological 
adverse reactions as worsening psychiatric symptoms may lead to overmedication and more 
severe adverse reactions (3,27). 
 
Psychiatric polypharmacy was common in our study, but it did not have a major effect on the 
follow-up practices. Children treated with an SGA plus ADHD medication were more likely to 
have their blood pressure measured at baseline compared to other patients. This was probably 
due to the existing national ADHD treatment guidelines which recommend repeated blood 
pressure measurements. Even though polypharmacy only had a minor effect on the follow-up 
practices, it had effects on the observed weight gain and blood pressure readings. Studies 
have reported that appetite loss and blood pressure elevation have been relatively common 
adverse reactions to psychostimulant treatment (14,15). These reactions were also observed 
in our study. Patients using an SGA plus ADHD medication at some point during the study 
were less likely to gain weight compared to other patients. However, their systolic blood 
pressure values were indicatively more likely to be hypertensive.  
 
In our study, the weight gain was most apparent in patients treated with just an SGA or an 
SGA plus melatonin. However, when melatonin was combined with an SGA, a weak 
association with more modest weight gain was observed, mostly appearing within the normal 
weight category.  In addition, hypertensive systolic blood pressure values were indicatively 
less frequent in patients using an SGA plus melatonin than in patients receiving other treatment 
regimens. A similar tendency was observed in previous studies of adults and adolescents 
(28,29), indicating that adding melatonin could reduce SGA-related metabolic effects. 
However, these studies had several methodological limitations, such as small sample sizes, 
short follow-up times and scarce information concerning children (28,29). On the other hand, 
in a study by Tuomi et al (2016), adding melatonin decreased insulin release and increased 
glucose concentrations in adults (30). Sleep disturbances are known comorbidities of 
psychiatric disorders and quality of sleep is known to affect weight and metabolic control (29). 
The finding that adding melatonin was associated with fewer SGA-induced metabolic 
adversities should encourage clinicians to pay special attention to the sleeping habits of these   
patients.  
 
SGA treatment, on its own or to augment ADHD medication, is a major risk factor for metabolic 
disturbances in children. Psychotropic polypharmacy may increase the risk of adverse drug 
reactions or sometimes diminish it. Special attention should be paid to detecting adverse 
tendencies, not just to absolute reference values. It is essential that patients are monitored 
when they start new medication and that they are followed up regularly. Our study shows that 
there is still an urgent need for improvement, as inadequate monitoring can mean that adverse 
reactions with far-reaching consequences are missed. Early interventions and lifestyle 
changes are effective ways of reducing the metabolic comorbidities of SGAs. However, the 
most effective tool is prevention, which is not possible without systematic monitoring.  
 
The major strengths of our research were the real-life nature of the study and long follow-up 
period. Our study provided an honest perspective on the clinical reality and disclosed major 
targets for interventions. The relatively small sample size, retrospective nature and the lack of 
a control group limit the generalisability of our results and they should be interpreted with 
caution. However, this study has laid the foundation for a more systematic follow-up procedure 
for SGA treatment in children at Tampere University Hospital. 
 
CONCLUSION  
Knowing the possible adverse drug reactions and being aware of the pitfalls in current practices 
of SGA treatment should encourage clinicians to adopt more systematic treatment procedures. 
The identification, follow up and management of SGA-related adverse reactions are important 
activities for patient safety and all treating physicians are responsible for carrying these out. 
 
ACKNOWLEDGEMENTS 
We wish to acknowledge the contribution of Dr Tuula Tamminen to the design of this study and 
Dr Tuija Poutanen for providing a paediatric cardiology advice about the blood pressure 
measurements.  
  
  
ABBREVIATIONS 
ADHD, attention deficit hyperactivity disorder; BMI, body mass index; HDL, high-density 
lipoproteins; IQR, lower to upper quartile; SGA, second-generation antipsychotic; BMI z-
score, standardised body mass index adjusted for age and sex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONFLICT OF INTERESTS 
The authors have no conflicts of interest to disclose.  
 
FUNDING 
This study was supported by the Foundation for Paediatric Research and the Finnish Brain 
Foundation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
REFERENCES 
1. Kalverdijk LJ, Bachmann CJ, Aagaard L, Burcu M, Glaeske G, Hoffmann F, et al. A multi-
national comparison of antipsychotic drug use in children and adolescents, 2005-2012. Child 
Adolesc Psychiatry Ment Health 2017; 11: 55 
2. Schneider C, Taylor D, Zalsman G, Frangou S, Kyriakopoulos M. Antipsychotics use in 
children and adolescents: an on-going challenge in clinical practice. J Psychopharmacol 
2014; 28: 615-23 
3. Rasimas JJ, Liebelt EL. Adverse effects and toxicity of the atypical antipsychotics: what is 
important for the pediatric emergency medicine practitioner? Clin Pediatr Emerg Med 2012; 
13: 300-10 
4. Kronstrom K, Kuosmanen L, Ellila H, Kaljonen A, Sourander A. National time trend 
changes in psychotropic medication of child and adolescent psychiatric inpatients across 
Finland. Child Adolesc Ment Health 2018; 23: 63-70 
5. Lohr WD, Creel L, Feygin Y, Stevenson M, Smith MJ, Myers J, et al. Psychotropic 
polypharmacy among children and youth receiving medicaid, 2012-2015. J Manag Care 
Spec Pharm 2018; 24: 736-44 
6. Martinez-Ortega JM, Funes-Godoy S, Diaz-Atienza F, Gutierrez-Rojas L, Perez-Costillas 
L, Gurpegui M. Weight gain and increase of body mass index among children and 
adolescents treated with antipsychotics: a critical review. Eur Child Adolesc Psychiatry 2013; 
22: 457-79 
7. Panagiotopoulos C, Ronsley R, Kuzeljevic B, Davidson J. Waist circumference is a 
sensitive screening tool for assessment of metabolic syndrome risk in children treated with 
second-generation antipsychotics. Can J Psychiatry 2012; 57: 34-44 
8. Nicol GE, Yingling MD, Flavin KS, Schweiger JA, Patterson BW, Schechtman KB, et al. 
Metabolic effects of antipsychotics on adiposity and insulin sensitivity in youths: a 
randomized clinical trial. JAMA Psychiatry 2018; 75: 788-96 
9. Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, et al. Type 2 diabetes 
mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA 
Psychiatry 2016; 73: 247-59 
10. Ray WA, Stein CM, Murray KT, Fuchs DC, Patrick SW, Daugherty J, et al. Association of 
antipsychotic treatment with risk of unexpected death among children and youths. JAMA 
Psychiatry 2019; 76: 162-71 
11. Carbon M, Kapoor S, Sheridan E, Al-Jadiri A, Azzo S, Sarkaria T, et al. Neuromotor 
adverse effects in 342 youth during 12 weeks of naturalistic treatment with 5 second-
generation antipsychotics. J Am Acad Child Adolesc Psychiatry 2015; 54: 718-727 
12. Garcia-Amador M, Merchan-Naranjo J, Tapia C, Moreno C, Castro-Fornieles J, Baeza I, 
et al. Neurological adverse effects of antipsychotics in children and adolescents. J Clin 
Psychopharmacol 2015; 35: 686-93 
13. Jahangard L, Akbarian S, Haghighi M, Ahmadpanah M, Keshavarzi A, Bajoghli H, et al. 
Children with ADHD and symptoms of oppositional defiant disorder improved in behavior 
when treated with methylphenidate and adjuvant risperidone, though weight gain was also 
observed - results from a randomized, double-blind, placebo-controlled clinical trial. 
Psychiatry Res 2017; 251: 182-91 
14. Díez-Suárez A, Vallejo-Valdivielso M, Marín-Méndez JJ, de Castro-Manglano P, Soutullo 
CA. Weight, height, and body mass index in patients with attention-deficit/hyperactivity 
disorder treated with methylphenidate. J Child Adolesc Psychopharmacol 2017; 27: 723-30 
15. Reed VA, Buitelaar JK, Anand E, Day KA, Treuer T, Upadhyaya HP, et al. The safety of 
atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity 
disorder: a comprehensive review of over a decade of research. CNS Drugs 2016; 30: 603-
28 
16. Kealey E, Scholle SH, Byron SC, Hoagwood K, Leckman-Westin E, Kelleher K, et al. 
Quality concerns in antipsychotic prescribing for youth: a review of treatment guidelines. 
Acad Pediatr 2014; 14 Suppl 5: 68-75 
17. Pringsheim T, Ho J, Sarna JR, Hammer T, Patten S. Feasibility and relevance of 
antipsychotic safety monitoring in children with tourette syndrome: a prospective longitudinal 
study. J Clin Psychopharmacol 2017; 37: 498-504 
18. Coughlin M, Goldie CL, Tranmer J, Khalid-Khan S, Tregunno D. Patient, treatment, and 
health care utilization variables associated with adherence to metabolic monitoring practices 
in children and adolescents taking second-generation antipsychotics. Can J Psychiatry 2018; 
63: 240-9 
19. Okumura Y, Usami M, Okada T, Saito T, Negoro H, Tsujii N, et al. Glucose and prolactin 
monitoring in children and adolescents initiating antipsychotic therapy. J Child Adolesc 
Psychopharmacol 2018; 28: 454-62 
20. Chen W, Cepoiu-Martin M, Stang A, Duncan D, Symonds C, Cooke L, et al. 
Antipsychotic prescribing and safety monitoring practices in children and youth: a population-
based study in Alberta, Canada. Clin Drug Investig 2018; 38: 449-55 
21. Saari A, Sankilampi U, Hannila M, Kiviniemi V, Kesseli K, Dunkel L. New Finnish growth 
references for children and adolescents aged 0 to 20 years: length/height-for-age, weight-for-
length/height, and body mass index-for-age. Ann Med 2011; 43: 235-48. 
22. Owens S, Galloway R. Childhood obesity and the metabolic syndrome. Curr Atheroscler 
Rep 2014; 16: 436 
23. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic 
syndrome phenotype in adolescents: findings from the third National Health and Nutrition 
Examination Survey, 1988-1994. Arch Pediatr Adolesc Med 2003; 157: 821-7 
24. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Clinical 
practice guideline for screening and management of high blood pressure in children and 
adolescents. Pediatrics 2017; 140: e20171904 
25. Kakko K, Pihlakoski L, Salmelin R, Keskinen P, Puura K, Tamminen T. Clinical use of 
second-generation antipsychotics in children. Scand J Child Adolesc Psychiatr Psychol 2017; 
5: 77-88 
26. Sjo CP, Stenstrøm AD, Bojesen AB, Frølich JS, Bilenberg N. Development of metabolic 
syndrome in drug-naive adolescents after 12 months of second-generation antipsychotic 
treatment. J Child Adolesc Psychopharmacol 2017; 27: 884-91 
27. Kakko K, Bjelogrlic-Laakso N, Pihlakoski L, Lehtimäki K, Järventausta K. Tardive 
dyskinesia should not be overlooked. J Child Adolesc Psychopharmacol 2019; 29: 72-74 
28. Agahi M, Akasheh N, Ahmadvand A, Akbari H, Izadpanah F. Effect of melatonin in 
reducing second-generation antipsychotic metabolic effects: a double blind controlled clinical 
trial. Diabetes Metab Syndr 2018; 12: 9-15 
29. Mostafavi S, Solhi M, Mohammadi M, Akhondzadeh S. Melatonin for reducing weight 
gain following administration of atypical antipsychotic olanzapine for adolescents with bipolar 
disorder: a randomized, double-blind, placebo-controlled trial. J Child Adolesc 
Psychopharmacol 2017; 27: 440-4 
30. Tuomi T, Nagorny CLF, Singh P, Bennet H, Yu Q, Alenkvist I, et al. Increased melatonin 
signaling is a risk factor for type 2 diabetes. Cell Metab 2016; 23: 1067-77 
 
Table 1. Background factors of the children treated with SGAs (n = 128). 
 
 % 
Gender  
Male 81 
Female 19 
Family status  
Biological parents 37 
One biological parent alone or with a 
new partner 
40 
Foster home 18 
Other (e.g. adoption) 6 
Number of ICD-10 F-diagnoses1  
1 26 
2 48 
3 23 
4 4 
In first-degree relatives, the availability 
of the history of2 
 
psychiatric disorders 84 
metabolic disorders 53 
Psychotropic medication other than an 
SGA3 
 
methylphenidate 65 
atomoxetine 23 
selective serotonin reuptake 
inhibitors 
14 
benzodiazepines4 14 
melatonin 63 
1 F00-F99 mental and behavioural disorders. 
2 Co-occurence was possible. 
3 At least a trial during the study period.  
4 As requisite medication. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Frequencies of somatic measurements and their abnormal values at the baseline and 
during the follow-up period (n = 128).  
 
Type of measurement Value 
considered 
abnormal 
Baseline During the entire study period, 
the proportion having 
at least one 
   
 
% 
measurement 
 
% 
abnormal 
value3 
% 
Physical examination - 34 78 - 
BMI1 > 252 34 92 46 
Fasting plasma high-density 
lipoprotein 
≤ 1.03 mmol/l  
40 
 
86 
 
20 
Fasting plasma triglyceride ≥ 1.24 mmol/l 39 86 27 
Fasting blood glucose > 6.1 mmol/l 49 95 7 
Blood pressure > 95th percentile 27 81 - 
 systolic  - - 40 
 diastolic  - - 21 
1 Standardised body mass index, adjusted for sex and age (BMI z-score) 
2 BMI z-score corresponding to BMI > 25. 
3 Among those who had at least one measurement. 
 
  
Table 3. Weight changes in medication groups. 
 
 Medication group1   
  SGA 
 
 
SGA + 
ADHD 
 
SGA + 
melatonin 
SGA + 
ADHD+ 
melatonin 
p All 
 
 
Patients who        
had > 2 simultaneous  (n = 23) (n = 25) (n = 21) (n = 59)  (n = 128) 
measurements of weight n 14 22 16 45 ns5 97 
and height available % 61 88 76 76  76 
        
  (n = 14) (n = 22) (n = 16) (n = 45)  (n = 97) 
did not gain weight n 1 8 0 15 0.0244 24 
 %2 7 36 0 33  25 
gained weight within n 5 7 11 17  40 
normal range %2 36 32 69 38  41 
gained weight within over-  n 8 7 5 13  33 
weight or obesity, or %2 57 32 31 29  34 
moved to either of them        
        
Change in standardised Md3 0.55 0.51 0.51 0.31 ns5 0.46 
body mass index, adjusted 
for age and sex 
IQR3 0.22– 
1.08 
-0.27–
1.14 
0.34– 
1.01 
-0.12–
0.73 
 0.04– 
0.92 
1 SGA = second-generation antipsychotic, ADHD: methylphenidate, atomoxetine, lisdexamfetamine (n 
= 1). 
2 % of those who had at least two measurements available. 
3 Md = Median, IQR = intra quartile range. 
4 Pearson’s chi-square test. 
5 Kolmogorov–Smirnov test. 
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Figure 1. The cumulative frequency distribution of the minimum and maximum BMI z-score 
(standardised body mass index, adjusted for sex and age) in children treated with SGAs (n = 97). 
 
 
